Genzyme Corp. has proposed to acquire AnorMED, Inc. of Vancouver, British Columbia in an all cash transaction valued at approximately $380 million. AnorMED’s leading late-stage product candidate, Mozobil, in development for hematopoietic stem cell transplantation (HSCT) could improve the viability of HSCT and enlarge the pool of patients for whom transplantation is an option. Enrollment is complete in a Phase III trial for Mozobil in multiple myeloma, and a second Phase III trial in non-Ho...